gatifloxacin has been researched along with erythromycin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Floyd, JL; Floyd, JT; Kumar, SH; Smith, KP; Varela, MF | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Dubois, J; St-Pierre, C | 1 |
| Beach, ML; Fluit, A; Jones, RN; Odland, BA; Verhoef, J | 1 |
| Cartwright, FD; Kenny, GE | 1 |
| Badaró, R; Bumroongkit, C; Corrêa, JC; Dolmann, AL; Juárez Martínez, LG; Mayrinck, LR; Mera, JR; Tamez, R; Yang, JY | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD | 1 |
1 trial(s) available for gatifloxacin and erythromycin
| Article | Year |
|---|---|
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral st
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Erythromycin; Female; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia | 2003 |
20 other study(ies) available for gatifloxacin and erythromycin
| Article | Year |
|---|---|
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
Topics: Amino Acid Sequence; Bacterial Proteins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Ethidium; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Onium Compounds; Organophosphorus Compounds; Phylogeny; Sequence Homology, Amino Acid; Sodium Dodecyl Sulfate; Staphylococcus aureus; Trimethoprim; Vancomycin | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cell Death; Cricetinae; Disease Models, Animal; Erythromycin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mesocricetus; Minocycline; Mycoplasma pneumoniae; Piperazines; Pneumonia, Mycoplasma; Quinolones | 1994 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Gatifloxacin; Legionella; Microbial Sensitivity Tests; Rifampin | 1999 |
Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveill
Topics: Anti-Infective Agents; Canada; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Erythromycin; Europe; Fluoroquinolones; Gatifloxacin; Humans; Latin America; Microbial Sensitivity Tests; Penicillins; Streptococcus pneumoniae; United States | 1999 |
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities
Topics: 4-Quinolones; Acetamides; Aminoglycosides; Anti-Bacterial Agents; Aza Compounds; Erythromycin; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Ketolides; Linezolid; Macrolides; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mycoplasma hominis; Mycoplasma pneumoniae; Oxazolidinones; Quinolines; Tetracyclines; Tigecycline; Ureaplasma urealyticum; Virginiamycin | 2001 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Topics: Adenosine; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Binding, Competitive; Biological Transport; Cell Line; Cell Polarity; Diketopiperazines; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gatifloxacin; Heterocyclic Compounds, 4 or More Rings; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Propionates; Quinidine; Quinolines; Transfection | 2010 |